These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1401 related items for PubMed ID: 28085680

  • 1. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM, Park K.
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [Abstract] [Full Text] [Related]

  • 2. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH, Soo RA.
    Drug Des Devel Ther; 2015 Mar; 9():5641-53. PubMed ID: 26508839
    [Abstract] [Full Text] [Related]

  • 3. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Liao BC, Lin CC, Yang JC.
    Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
    [Abstract] [Full Text] [Related]

  • 4. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ, Drilon A, Santini FC.
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [Abstract] [Full Text] [Related]

  • 5. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS, Cho BC, Soo RA.
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.
    Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zanghì M, Rolfo C, Adamo V.
    Crit Rev Oncol Hematol; 2017 Sep; 117():38-47. PubMed ID: 28807234
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F.
    Oncotarget; 2017 Apr 04; 8(14):23020-23032. PubMed ID: 28416737
    [Abstract] [Full Text] [Related]

  • 9. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.
    Noda S, Kanda S.
    Expert Rev Respir Med; 2016 Apr 04; 10(5):547-56. PubMed ID: 26959310
    [Abstract] [Full Text] [Related]

  • 10. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
    Walia M, Singhal MK, Kamle MS.
    Indian J Cancer; 2022 Mar 04; 59(Supplement):S80-S89. PubMed ID: 35343193
    [Abstract] [Full Text] [Related]

  • 11. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D.
    Clin Cancer Res; 2016 Oct 15; 22(20):5130-5140. PubMed ID: 27435396
    [Abstract] [Full Text] [Related]

  • 12. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.
    Batra U, Lokeshwar N, Gupta S, Shirsath P.
    Indian J Cancer; 2017 Dec 15; 54(Supplement):S37-S44. PubMed ID: 29292707
    [Abstract] [Full Text] [Related]

  • 13. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH.
    Oncologist; 2015 Mar 15; 20(3):307-15. PubMed ID: 25657199
    [Abstract] [Full Text] [Related]

  • 14. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.
    Lim SM, Syn NL, Cho BC, Soo RA.
    Cancer Treat Rev; 2018 Apr 15; 65():1-10. PubMed ID: 29477930
    [Abstract] [Full Text] [Related]

  • 15. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors.
    Singh M, Jadhav HR.
    Drug Discov Today; 2018 Mar 15; 23(3):745-753. PubMed ID: 29031620
    [Abstract] [Full Text] [Related]

  • 16. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].
    Asami K.
    Gan To Kagaku Ryoho; 2014 May 15; 41(5):533-8. PubMed ID: 24916999
    [Abstract] [Full Text] [Related]

  • 17. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK, Kim S, Lee JS, Lee JE, Kim SM, Yang IS, Kim HR, Lee JH, Kim S, Cho BC.
    Lung Cancer; 2017 Nov 15; 113():106-114. PubMed ID: 29110836
    [Abstract] [Full Text] [Related]

  • 18. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K, Yuan Q.
    J Cancer Res Ther; 2016 Dec 15; 12(Supplement):C131-C137. PubMed ID: 28230005
    [Abstract] [Full Text] [Related]

  • 19. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
    Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Inaba Y, Hida T, Yatabe Y.
    Clin Lung Cancer; 2017 Nov 15; 18(6):698-705.e2. PubMed ID: 28596108
    [Abstract] [Full Text] [Related]

  • 20. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
    Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K.
    Clin Lung Cancer; 2017 Nov 15; 18(6):719-723. PubMed ID: 28623122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.